FREE NEJM E-TOC    HOME   |   SUBSCRIBE   |   CURRENT ISSUE   |   PAST ISSUES   |   COLLECTIONS   |   Search Term  Advanced Search

Sign in | Get NEJM's E-Mail Table of Contents — Free | Subscribe

Previous Volume 355:1037-1046 September 7, 2006 Number 10 Next

	Since this article has no abstract, we have provided an extract of the first 100 words of the full text and any section headings.

	Full Text PDF PDA Full Text PowerPoint Slide Set Purchase this article Add to Personal Archive Add to Citation Manager Notify a Friend E-mail When Cited E-mail When Letters Appear PubMed Citation

In many tissues, there are numerous small and inconspicuous neoplastic lesions that rarely become overt cancers. In these small lesions, clonality and oncogenic mutations have been identified. These lesions include established benign tumors such as melanocytic nevi,¹ some that were previously regarded to be of a "reactive" nature,² and even groups of cells that are histologically only marginally abnormal.³ Once they have grown to a certain size, such lesions stop growing appreciably and do not become more aggressive over many years or even decades. For instance, few moles, which are benign tumors of cutaneous melanocytes, grow larger than 1 cm, . . . [Full Text of this Article]

Oncogene-Induced Proliferative Arrest

Aberrant Proliferative Signaling and Disruption of Cell-Cycle Checkpoints

Telomeres, Replicative Senescence, and Disease

Other Mechanisms of Cellular Senescence

Nevi, Melanomas, p16^INK4A, and Senescence

Telomeric Insufficiency, DNA Damage, and Oncogenic Stress

Senescence and Apoptosis

Future Prospects

Source Information

From the Department of Pathology, Vrije University Medical Center (W.J.M.), and the Division of Molecular Genetics, Netherlands Cancer Institute (D.S.P.) — both in Amsterdam.

Address reprint requests to Dr. Mooi at the Department of Pathology, Vrije University Medical Center, De Boelelaan 1117, 1081 HV Amsterdam, the Netherlands, or at wj.mooi@vumc.nl.

This article has been cited by other articles:

• Aubert, G., Lansdorp, P. M. (2008). Telomeres and Aging. Physiol. Rev. 88: 557-579 [Abstract] [Full Text]  
• Welch, H. G., Woloshin, S., Schwartz, L. M. (2008). The Sea of Uncertainty Surrounding Ductal Carcinoma In Situ--The Price of Screening Mammography. JNCI J Natl Cancer Inst 100: 228-229 [Full Text]  
• Welch, H. G., Woloshin, S., Schwartz, L. M., Gordis, L., Gotzsche, P. C., Harris, R., Kramer, B. S., Ransohoff, D. F. (2007). Overstating the Evidence for Lung Cancer Screening: The International Early Lung Cancer Action Program (I-ELCAP) Study. Arch Intern Med 167: 2289-2295 [Abstract] [Full Text]  
• Heiss, E. H., Schilder, Y. D. C., Dirsch, V. M. (2007). Chronic Treatment with Resveratrol Induces Redox Stress- and Ataxia Telangiectasia-mutated (ATM)-dependent Senescence in p53-positive Cancer Cells. J. Biol. Chem. 282: 26759-26766 [Abstract] [Full Text]  
• Efeyan, A., Ortega-Molina, A., Velasco-Miguel, S., Herranz, D., Vassilev, L. T., Serrano, M. (2007). Induction of p53-Dependent Senescence by the MDM2 Antagonist Nutlin-3a in Mouse Cells of Fibroblast Origin. Cancer Res. 67: 7350-7357 [Abstract] [Full Text]  
• Bataille, V., Kato, B. S., Falchi, M., Gardner, J., Kimura, M., Lens, M., Perks, U., Valdes, A. M., Bennett, D. C., Aviv, A., Spector, T. D. (2007). Nevus Size and Number Are Associated with Telomere Length and Represent Potential Markers of a Decreased Senescence In vivo. Cancer Epidemiol. Biomarkers Prev. 16: 1499-1502 [Abstract] [Full Text]  
• Ha, L., Ichikawa, T., Anver, M., Dickins, R., Lowe, S., Sharpless, N. E., Krimpenfort, P., DePinho, R. A., Bennett, D. C., Sviderskaya, E. V., Merlino, G. (2007). ARF functions as a melanoma tumor suppressor by inducing p53-independent senescence. Proc. Natl. Acad. Sci. USA 104: 10968-10973 [Abstract] [Full Text]  
• Hornsby, P. J. (2007). Senescence As an Anticancer Mechanism. JCO 25: 1852-1857 [Abstract] [Full Text]  
• Maity, A., Koumenis, C. (2006). HIF and MIF--a nifty way to delay senescence?. Genes Dev. 20: 3337-3341 [Full Text]